Hyperoxia During Pulmonary Rehabilitation in Chronic Lung Disease - Does it Matter?

Last updated: July 22, 2024
Sponsor: Eastern Switzerland University of Applied Sciences
Overall Status: Active - Recruiting

Phase

N/A

Condition

Scleroderma

Heart Disease

Cardiovascular Disease

Treatment

Oxygen

Clinical Study ID

NCT06174207
RehaExO2
  • Ages > 18
  • All Genders

Study Summary

Chronic respiratory diseases are a global burden. Treatment options have improved in recent years, pulmonary rehabilitation plays a key role. Oxygen therapy is recommended in patients with a low saturation at rest, but no clear guidance is given for patients who desaturate during exercise. The effect of ambulatory oxygen during exercise is not yet completely understood, especially in those patients with exercise-induced desaturation.

Aim: The goal of this study is to analyse the effect of supplemental oxygen given during a constant work rate exercise test (CWRET) on a cycle ergometer compared to sham air.

Methods: We plan to include 25 Patients respiratory patients undergoing pulmonary rehabilitation (male and female; aged >18 years; stable condition >3 weeks (e.g. no exacerbations); resting oxygen saturation (SpO2) ≥ 88%) with exercise induced hypoxemia defined by a fall in oxygen saturation by ≥ 4% during a 6-minute walking test. Patients will undergo an incremental exercise test with a ramp protocol (for evaluating the maximal workload) and two CWRET (75% of the maximal workload) with ambulatory oxygen or placebo (sham air) via standard nasal canula at a flow rate of 5l/min. Patients and assessors will be blinded. The difference endurance time of the CWRET with oxygen vs. sham air will be the primary outcome of this study.

Data will be summarized by means (SD) and medians (quartiles) for normal and non-normal distributions. Effects of treatment will be evaluated by mean differences with 95% confidence intervals, T-tests or Wilcoxon matched pair tests as appropriate. A p-value threshold of <0.05 or a confidence interval not including zero will be considered as statistically significant. Analyses will be performed according to the intention to treat principle.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • We will include male and female lung disease patients undergoing pulmonaryrehabilitation: aged ≥ 18 years; stable condition > 3 weeks (e.g. no exacerbations);resting oxygen saturation (SpO2) ≥ 88% and exercise induced hypoxemia defined by afall in SpO2 by ≥ 4% during a 6-minute walking test (6MWT); informed consent asdocumented by signature.

Exclusion

Exclusion Criteria:

  • Severe daytime resting hypoxemia (SpO2 < 88% or partial pressure of oxygen (PaO2) < 8 kPa); unstable condition requiring adaptation of pharmacologic and other treatmentmodalities or requirement of intensive care or relevant severe concomitant disease;inability to follow the procedures of the study, e.g. due to language problems,psychological disorders, neurological or orthopedic problems with walking disabilityor inability to ride a bicycle; women who are pregnant or breast feeding; enrolmentin another clinical trial with active treatment.

Study Design

Total Participants: 25
Treatment Group(s): 1
Primary Treatment: Oxygen
Phase:
Study Start date:
January 24, 2024
Estimated Completion Date:
April 30, 2025

Connect with a study center

  • Kantonsspital Winterthur

    Winterthur, Zürich 8400
    Switzerland

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.